During the past decade, Shanghai Tong Ren Hospital conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shanghai Tong Ren Hospital" #1 sponsor was "Loxo Oncology, Inc." with 2 trials, followed by "Shanghai Tong Ren Hospital" with 2 trials sponsored, "RenJi Hospital" with 1 trials sponsored, "Shanghai 10th People's Hospital" with 1 trials sponsored and "Shanghai HEP Pharmaceutical Co., Ltd." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shanghai Tong Ren Hospital" #1 collaborator was "Shanghai Tong Ren Hospital" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "The First Affiliated Hospital of Zhengzhou University" with 2 trials as a collaborator, "First Affiliated Hospital of Guangxi Medical University" with 1 trials as a collaborator and "Gracell Biotechnology Ltd." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Shanghai Tong Ren Hospital" are "Chronic Lymphocytic Leukemia" (2 trials), "Small Lymphocytic Lymphoma" (2 trials), "Acute Myeloid Leukemia" (1 trials), "Acute Myocardial Infarction" (1 trials) and "Atrial Fibrillation New Onset" (1 trials). Many other conditions were trialed in "Shanghai Tong Ren Hospital" in a lesser frequency.

Most popular intervention types in "Shanghai Tong Ren Hospital" are "Drug" (6 trials), "Biological" (1 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pirtobrutinib" (2 trials), "Rituximab" (2 trials), "All-transretinoic acid" (1 trials), "Auto-HSCT" (1 trials) and "Bendamustine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Shanghai Tong Ren Hospital" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Shanghai Tong Ren Hospital". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Shanghai Tong Ren Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Shanghai Tong Ren Hospital, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".